

Global Lucentis (Ranibizumab) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/G252279F7853EN.html>

Date: June 2023

Pages: 74

Price: US\$ 3,480.00 (Single User License)

ID: G252279F7853EN

Abstracts

According to our (Global Info Research) latest study, the global Lucentis (Ranibizumab) and Biosimilar market size was valued at USD 1156.5 million in 2022 and is forecast to a readjusted size of USD 971.5 million by 2029 with a CAGR of -2.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy.

This report is a detailed and comprehensive analysis for global Lucentis (Ranibizumab) and Biosimilar market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Lucentis (Ranibizumab) and Biosimilar market size and forecasts, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Lucentis (Ranibizumab) and Biosimilar market size and forecasts by region and

country, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Lucentis (Ranibizumab) and Biosimilar market size and forecasts, by Type and by Application, in consumption value (\$ Million), sales quantity (K Units), and average selling prices (US\$/Unit), 2018-2029

Global Lucentis (Ranibizumab) and Biosimilar market shares of main players, shipments in revenue (\$ Million), sales quantity (K Units), and ASP (US\$/Unit), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Lucentis (Ranibizumab) and Biosimilar

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Lucentis (Ranibizumab) and Biosimilar market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Coherus and Biogen. etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation

Lucentis (Ranibizumab) and Biosimilar market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Brand

Biosimilar

Market segment by Application

Hospital

Pharmacy

Other

Major players covered

Roche

Coherus

Biogen

Market segment by region, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Lucentis (Ranibizumab) and Biosimilar product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Lucentis (Ranibizumab) and Biosimilar, with price, sales, revenue and global market share of Lucentis (Ranibizumab) and Biosimilar from 2018 to 2023.

Chapter 3, the Lucentis (Ranibizumab) and Biosimilar competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Lucentis (Ranibizumab) and Biosimilar breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.

Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022. and Lucentis (Ranibizumab) and Biosimilar market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.

Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.

Chapter 13, the key raw materials and key suppliers, and industry chain of Lucentis (Ranibizumab) and Biosimilar.

Chapter 14 and 15, to describe Lucentis (Ranibizumab) and Biosimilar sales channel, distributors, customers, research findings and conclusion.

Contents

1 MARKET OVERVIEW

- 1.1 Product Overview and Scope of Lucentis (Ranibizumab) and Biosimilar
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
 - 1.3.1 Overview: Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Type: 2018 Versus 2022 Versus 2029
 - 1.3.2 Brand
 - 1.3.3 Biosimilar
- 1.4 Market Analysis by Application
 - 1.4.1 Overview: Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Application: 2018 Versus 2022 Versus 2029
 - 1.4.2 Hospital
 - 1.4.3 Pharmacy
 - 1.4.4 Other
- 1.5 Global Lucentis (Ranibizumab) and Biosimilar Market Size & Forecast
 - 1.5.1 Global Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018 & 2022 & 2029)
 - 1.5.2 Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity (2018-2029)
 - 1.5.3 Global Lucentis (Ranibizumab) and Biosimilar Average Price (2018-2029)

2 MANUFACTURERS PROFILES

- 2.1 Roche
 - 2.1.1 Roche Details
 - 2.1.2 Roche Major Business
 - 2.1.3 Roche Lucentis (Ranibizumab) and Biosimilar Product and Services
 - 2.1.4 Roche Lucentis (Ranibizumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.1.5 Roche Recent Developments/Updates
- 2.2 Coherus
 - 2.2.1 Coherus Details
 - 2.2.2 Coherus Major Business
 - 2.2.3 Coherus Lucentis (Ranibizumab) and Biosimilar Product and Services
 - 2.2.4 Coherus Lucentis (Ranibizumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
 - 2.2.5 Coherus Recent Developments/Updates

2.3 Biogen

2.3.1 Biogen Details

2.3.2 Biogen Major Business

2.3.3 Biogen Lucentis (Ranibizumab) and Biosimilar Product and Services

2.3.4 Biogen Lucentis (Ranibizumab) and Biosimilar Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)

2.3.5 Biogen Recent Developments/Updates

3 COMPETITIVE ENVIRONMENT: LUCENTIS (RANIBIZUMAB) AND BIOSIMILAR BY MANUFACTURER

3.1 Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Manufacturer (2018-2023)

3.2 Global Lucentis (Ranibizumab) and Biosimilar Revenue by Manufacturer (2018-2023)

3.3 Global Lucentis (Ranibizumab) and Biosimilar Average Price by Manufacturer (2018-2023)

3.4 Market Share Analysis (2022)

3.4.1 Producer Shipments of Lucentis (Ranibizumab) and Biosimilar by Manufacturer Revenue (\$MM) and Market Share (%): 2022

3.4.2 Top 3 Lucentis (Ranibizumab) and Biosimilar Manufacturer Market Share in 2022

3.4.2 Top 6 Lucentis (Ranibizumab) and Biosimilar Manufacturer Market Share in 2022

3.5 Lucentis (Ranibizumab) and Biosimilar Market: Overall Company Footprint Analysis

3.5.1 Lucentis (Ranibizumab) and Biosimilar Market: Region Footprint

3.5.2 Lucentis (Ranibizumab) and Biosimilar Market: Company Product Type Footprint

3.5.3 Lucentis (Ranibizumab) and Biosimilar Market: Company Product Application

Footprint

3.6 New Market Entrants and Barriers to Market Entry

3.7 Mergers, Acquisition, Agreements, and Collaborations

4 CONSUMPTION ANALYSIS BY REGION

4.1 Global Lucentis (Ranibizumab) and Biosimilar Market Size by Region

4.1.1 Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Region (2018-2029)

4.1.2 Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Region (2018-2029)

4.1.3 Global Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2018-2029)

4.2 North America Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029)

4.3 Europe Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029)

4.4 Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029)

4.5 South America Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029)

4.6 Middle East and Africa Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029)

5 MARKET SEGMENT BY TYPE

5.1 Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2029)

5.2 Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Type (2018-2029)

5.3 Global Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2029)

6 MARKET SEGMENT BY APPLICATION

6.1 Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2029)

6.2 Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Application (2018-2029)

6.3 Global Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2029)

7 NORTH AMERICA

7.1 North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2029)

7.2 North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2029)

7.3 North America Lucentis (Ranibizumab) and Biosimilar Market Size by Country

7.3.1 North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2018-2029)

7.3.2 North America Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2018-2029)

7.3.3 United States Market Size and Forecast (2018-2029)

7.3.4 Canada Market Size and Forecast (2018-2029)

7.3.5 Mexico Market Size and Forecast (2018-2029)

8 EUROPE

8.1 Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2029)

8.2 Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2029)

8.3 Europe Lucentis (Ranibizumab) and Biosimilar Market Size by Country

8.3.1 Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2018-2029)

8.3.2 Europe Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2018-2029)

8.3.3 Germany Market Size and Forecast (2018-2029)

8.3.4 France Market Size and Forecast (2018-2029)

8.3.5 United Kingdom Market Size and Forecast (2018-2029)

8.3.6 Russia Market Size and Forecast (2018-2029)

8.3.7 Italy Market Size and Forecast (2018-2029)

9 ASIA-PACIFIC

9.1 Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2029)

9.2 Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2029)

9.3 Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Market Size by Region

9.3.1 Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Region (2018-2029)

9.3.2 Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Consumption Value by Region (2018-2029)

9.3.3 China Market Size and Forecast (2018-2029)

9.3.4 Japan Market Size and Forecast (2018-2029)

9.3.5 Korea Market Size and Forecast (2018-2029)

9.3.6 India Market Size and Forecast (2018-2029)

9.3.7 Southeast Asia Market Size and Forecast (2018-2029)

9.3.8 Australia Market Size and Forecast (2018-2029)

10 SOUTH AMERICA

10.1 South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2029)

10.2 South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2029)

10.3 South America Lucentis (Ranibizumab) and Biosimilar Market Size by Country

10.3.1 South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2018-2029)

10.3.2 South America Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2018-2029)

10.3.3 Brazil Market Size and Forecast (2018-2029)

10.3.4 Argentina Market Size and Forecast (2018-2029)

11 MIDDLE EAST & AFRICA

11.1 Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2029)

11.2 Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2029)

11.3 Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Market Size by Country

11.3.1 Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2018-2029)

11.3.2 Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2018-2029)

11.3.3 Turkey Market Size and Forecast (2018-2029)

11.3.4 Egypt Market Size and Forecast (2018-2029)

11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)

11.3.6 South Africa Market Size and Forecast (2018-2029)

12 MARKET DYNAMICS

12.1 Lucentis (Ranibizumab) and Biosimilar Market Drivers

12.2 Lucentis (Ranibizumab) and Biosimilar Market Restraints

12.3 Lucentis (Ranibizumab) and Biosimilar Trends Analysis

12.4 Porters Five Forces Analysis

12.4.1 Threat of New Entrants

12.4.2 Bargaining Power of Suppliers

12.4.3 Bargaining Power of Buyers

12.4.4 Threat of Substitutes

12.4.5 Competitive Rivalry

12.5 Influence of COVID-19 and Russia-Ukraine War

12.5.1 Influence of COVID-19

12.5.2 Influence of Russia-Ukraine War

13 RAW MATERIAL AND INDUSTRY CHAIN

13.1 Raw Material of Lucentis (Ranibizumab) and Biosimilar and Key Manufacturers

13.2 Manufacturing Costs Percentage of Lucentis (Ranibizumab) and Biosimilar

13.3 Lucentis (Ranibizumab) and Biosimilar Production Process

13.4 Lucentis (Ranibizumab) and Biosimilar Industrial Chain

14 SHIPMENTS BY DISTRIBUTION CHANNEL

14.1 Sales Channel

14.1.1 Direct to End-User

14.1.2 Distributors

14.2 Lucentis (Ranibizumab) and Biosimilar Typical Distributors

14.3 Lucentis (Ranibizumab) and Biosimilar Typical Customers

15 RESEARCH FINDINGS AND CONCLUSION

16 APPENDIX

16.1 Methodology

16.2 Research Process and Data Source

16.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Roche Basic Information, Manufacturing Base and Competitors

Table 4. Roche Major Business

Table 5. Roche Lucentis (Ranibizumab) and Biosimilar Product and Services

Table 6. Roche Lucentis (Ranibizumab) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 7. Roche Recent Developments/Updates

Table 8. Coherus Basic Information, Manufacturing Base and Competitors

Table 9. Coherus Major Business

Table 10. Coherus Lucentis (Ranibizumab) and Biosimilar Product and Services

Table 11. Coherus Lucentis (Ranibizumab) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 12. Coherus Recent Developments/Updates

Table 13. Biogen Basic Information, Manufacturing Base and Competitors

Table 14. Biogen Major Business

Table 15. Biogen Lucentis (Ranibizumab) and Biosimilar Product and Services

Table 16. Biogen Lucentis (Ranibizumab) and Biosimilar Sales Quantity (K Units), Average Price (US\$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 17. Biogen Recent Developments/Updates

Table 18. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Manufacturer (2018-2023) & (K Units)

Table 19. Global Lucentis (Ranibizumab) and Biosimilar Revenue by Manufacturer (2018-2023) & (USD Million)

Table 20. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US\$/Unit)

Table 21. Market Position of Manufacturers in Lucentis (Ranibizumab) and Biosimilar, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022

Table 22. Head Office and Lucentis (Ranibizumab) and Biosimilar Production Site of Key Manufacturer

Table 23. Lucentis (Ranibizumab) and Biosimilar Market: Company Product Type Footprint

Table 24. Lucentis (Ranibizumab) and Biosimilar Market: Company Product Application Footprint

Table 25. Lucentis (Ranibizumab) and Biosimilar New Market Entrants and Barriers to Market Entry

Table 26. Lucentis (Ranibizumab) and Biosimilar Mergers, Acquisition, Agreements, and Collaborations

Table 27. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 28. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 29. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 30. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 31. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2018-2023) & (US\$/Unit)

Table 32. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2024-2029) & (US\$/Unit)

Table 33. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 34. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 35. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Type (2018-2023) & (USD Million)

Table 36. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Type (2024-2029) & (USD Million)

Table 37. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2023) & (US\$/Unit)

Table 38. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2024-2029) & (US\$/Unit)

Table 39. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 40. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 41. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Application (2018-2023) & (USD Million)

Table 42. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by

Application (2024-2029) & (USD Million)

Table 43. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2023) & (US\$/Unit)

Table 44. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2024-2029) & (US\$/Unit)

Table 45. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 46. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 47. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 48. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 49. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 50. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 51. North America Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 52. North America Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 53. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 54. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 55. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 56. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 57. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 58. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 59. Europe Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 60. Europe Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 61. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 62. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 63. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 64. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 65. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Region (2018-2023) & (K Units)

Table 66. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 67. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 68. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 69. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 70. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 71. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 72. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 73. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2018-2023) & (K Units)

Table 74. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Country (2024-2029) & (K Units)

Table 75. South America Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2018-2023) & (USD Million)

Table 76. South America Lucentis (Ranibizumab) and Biosimilar Consumption Value by Country (2024-2029) & (USD Million)

Table 77. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2018-2023) & (K Units)

Table 78. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Type (2024-2029) & (K Units)

Table 79. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2018-2023) & (K Units)

Table 80. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Application (2024-2029) & (K Units)

Table 81. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by

Region (2018-2023) & (K Units)

Table 82. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity by Region (2024-2029) & (K Units)

Table 83. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Consumption Value by Region (2018-2023) & (USD Million)

Table 84. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Consumption Value by Region (2024-2029) & (USD Million)

Table 85. Lucentis (Ranibizumab) and Biosimilar Raw Material

Table 86. Key Manufacturers of Lucentis (Ranibizumab) and Biosimilar Raw Materials

Table 87. Lucentis (Ranibizumab) and Biosimilar Typical Distributors

Table 88. Lucentis (Ranibizumab) and Biosimilar Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Lucentis (Ranibizumab) and Biosimilar Picture

Figure 2. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Figure 3. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Type in 2022

Figure 4. Brand Examples

Figure 5. Biosimilar Examples

Figure 6. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Figure 7. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Application in 2022

Figure 8. Hospital Examples

Figure 9. Pharmacy Examples

Figure 10. Other Examples

Figure 11. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value, (USD Million): 2018 & 2022 & 2029

Figure 12. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value and Forecast (2018-2029) & (USD Million)

Figure 13. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity (2018-2029) & (K Units)

Figure 14. Global Lucentis (Ranibizumab) and Biosimilar Average Price (2018-2029) & (US\$/Unit)

Figure 15. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Manufacturer in 2022

Figure 16. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Manufacturer in 2022

Figure 17. Producer Shipments of Lucentis (Ranibizumab) and Biosimilar by Manufacturer Sales Quantity (\$MM) and Market Share (%): 2021

Figure 18. Top 3 Lucentis (Ranibizumab) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022

Figure 19. Top 6 Lucentis (Ranibizumab) and Biosimilar Manufacturer (Consumption Value) Market Share in 2022

Figure 20. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 21. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value Market

Share by Region (2018-2029)

Figure 22. North America Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 23. Europe Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 24. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 25. South America Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 26. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Consumption Value (2018-2029) & (USD Million)

Figure 27. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 28. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Type (2018-2029)

Figure 29. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2029) & (US\$/Unit)

Figure 30. Global Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 31. Global Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Application (2018-2029)

Figure 32. Global Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2029) & (US\$/Unit)

Figure 33. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 34. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 35. North America Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 36. North America Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 37. United States Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 38. Canada Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 39. Mexico Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 40. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 41. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 42. Europe Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 43. Europe Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 44. Germany Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 45. France Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 46. United Kingdom Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 47. Russia Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 48. Italy Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 49. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 50. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 51. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 52. Asia-Pacific Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 53. China Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 54. Japan Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 55. Korea Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 56. India Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 57. Southeast Asia Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 58. Australia Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 59. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 60. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market

Share by Application (2018-2029)

Figure 61. South America Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Country (2018-2029)

Figure 62. South America Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Country (2018-2029)

Figure 63. Brazil Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 64. Argentina Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 65. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Type (2018-2029)

Figure 66. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Application (2018-2029)

Figure 67. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Sales Quantity Market Share by Region (2018-2029)

Figure 68. Middle East & Africa Lucentis (Ranibizumab) and Biosimilar Consumption Value Market Share by Region (2018-2029)

Figure 69. Turkey Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 70. Egypt Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 71. Saudi Arabia Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 72. South Africa Lucentis (Ranibizumab) and Biosimilar Consumption Value and Growth Rate (2018-2029) & (USD Million)

Figure 73. Lucentis (Ranibizumab) and Biosimilar Market Drivers

Figure 74. Lucentis (Ranibizumab) and Biosimilar Market Restraints

Figure 75. Lucentis (Ranibizumab) and Biosimilar Market Trends

Figure 76. Porters Five Forces Analysis

Figure 77. Manufacturing Cost Structure Analysis of Lucentis (Ranibizumab) and Biosimilar in 2022

Figure 78. Manufacturing Process Analysis of Lucentis (Ranibizumab) and Biosimilar

Figure 79. Lucentis (Ranibizumab) and Biosimilar Industrial Chain

Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors

Figure 81. Direct Channel Pros & Cons

Figure 82. Indirect Channel Pros & Cons

Figure 83. Methodology

Figure 84. Research Process and Data Source

I would like to order

Product name: Global Lucentis (Ranibizumab) and Biosimilar Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/G252279F7853EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G252279F7853EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

